Eli Lilly’s $3.2 billion acquisition of Kelonia Therapeutics draws on new data for an in vivo CAR-T approach. Coverage highlighted an “in vivo CAR-T” dataset with a reported 100% response rate as part of internal positioning for the deal. While details of durability and long-term safety were not provided in the excerpted report, the information is tied directly to why Lilly justified paying for Kelonia’s platform. For the sector, the readout reinforces how in vivo CAR-T programs are shifting from early feasibility into commercial-decision inputs for big buyers. The acquisition also underscores that major oncology platform bets increasingly hinge on early response signals even as follow-up maturation becomes the key next hurdle.